Impact of Covid-19 on Rhinovirus Epidemic
IPCoRV
Impact of Covid-19 Pandemic on the Epidemiology of Rhinovirus
1 other identifier
observational
400
0 countries
N/A
Brief Summary
Rhinovirus (RV) has long been known as the main etiological agent of "common colds" among children and adults. Indeed, RV is involved in more than 50% of upper respiratory tract infections (URTIs), mostly characterized by nasal congestion, rhinorrhea, sore throat and cough. RV can also cause mild to severe lower respiratory tract infections (LRTIs) such as acute bronchiolitis, pneumonia and exacerbations of underlying chronic lung diseases. RV circulates worldwide, especially in temperate climate zones (i.e. many areas of the USA and Europe) and is responsible for annual outbreaks from early fall to the end of spring. The covid-19 pandemic in 2020 seemed to interfere with the usual seasonal epidemics. For example, the winter Respiratory Syncytial Virus (RSV) epidemic in Lyon, France, was delayed for several months and reduced by half in terms of incidence of hospitalization cases. This can be explained by the widespread deployment of barrier gestures and social distancing measures, known as "non pharmacological interventions" (NPI). However, the Covid-19 pandemic doesn't seem to have the same reducing impact on Rhinovirus epidemic. A better understanding of viral interactions and factors influencing RV epidemiology as well as the identification of populations at greater risk are required to improve preventive strategies and reduce the burden of Rhinovirus.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2022
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 17, 2022
CompletedFirst Posted
Study publicly available on registry
April 27, 2022
CompletedStudy Start
First participant enrolled
May 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2023
CompletedApril 27, 2022
February 1, 2022
11 months
February 17, 2022
April 26, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Evolution of the number of children hospitalized for a Rhinovirus-infection in the period of pre Covid-19 pandemic.
Description of number of clinical picture cases for pre-SARS-CoV-2 pandemic year.
From one year before the SARS-CoV-2 pandemic until the beginning of the SARS-CoV-2 pandemic
Evolution of the number of children hospitalized for a Rhinovirus-infection in the period of per-Covid-19 pandemic.
Description of number of clinical picture cases for per-SARS-CoV-2 pandemic year.
From the beginning of the SARS-CoV-2 pandemic until one year latter
Study Arms (3)
Pre Covid 19 cohort
Infants hospitalized in the Pediatric Department of the " Hôpital Femme Mère Enfant ", Lyon, France with a RT-PCR positive for Rhinovirus from 17th March 2019 to 16th March 2020.
Per Covid 19 cohort year 1
Infant hospitalized in the Pediatric Department of the " Hôpital Femme Mère Enfant ", Lyon, France with a RT-PCR positive for Rhinovirus from 17th March 2020 to 16th March 2021. The need to recruit patients for an additional per-covid year (from 17th March 2021 to 16th March 2022) will be evaluated after the data from the first 2 years of recruitment are available.
Per Covid 19 cohort, year 2
Infants hospitalized in the Pediatric Department of the " Hôpital Femme Mère Enfant ", Lyon, France with a RT-PCR positive for Rhinovirus from 17th March 2021 to 16th March 2022. The need to recruit patients for this additional cohort will be evaluated after the data from the first 2 years of recruitment are available and analyzed.
Interventions
To review medical records to describe diagnosis and severity of the disease.
Eligibility Criteria
Child hospitalized at the " Hopital Femme Mere Enfant ", Lyon, France \- Positive rhinovirus-PCR
You may qualify if:
- \- Child hospitalized at the " Hopital Femme Mere Enfant ", Lyon, France
- Positive rhinovirus-PCR
You may not qualify if:
- \- parent's refusal to participate
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 17, 2022
First Posted
April 27, 2022
Study Start
May 1, 2022
Primary Completion
April 1, 2023
Study Completion
May 1, 2023
Last Updated
April 27, 2022
Record last verified: 2022-02